Abstract
Sudden cardiac death is the leading single cause of death in the western world. Especially patients after myocardial infarction and patients with heart failure are at increased risk. Proof of a severely reduced left ventricular ejection fraction is the gold standard for the identification of high risk patients, however its sensitivity and specificity are insufficient. Thereby two thirds of patients who die following a myocardial infarction, are not correctly identified as high risk patients. Biosignal-based parameters which quantify disturbances of the cardiac autonomous nervous systems may allow identification of high risk patients independently from left ventricular ejection fraction. These markers can be calculated using mathematical methods from a conventional surface ECG. SMART-MI is a randomized trial that evaluates the efficacy of a novel personalized approach to post-infarction treatment based on remote monitoring in patients with cardiac autonomic dysfunction and only moderately reduced left ventricular function.
Item Type: | Journal article |
---|---|
Faculties: | Medicine |
Subjects: | 600 Technology > 610 Medicine and health |
ISSN: | 2193-5203 |
Language: | German |
Item ID: | 64921 |
Date Deposited: | 19. Jul 2019, 12:16 |
Last Modified: | 04. Nov 2020, 13:44 |